Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Cipla
Deloitte
Medtronic
Merck
Queensland Health
McKinsey
Express Scripts
Dow

Generated: May 23, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021610

« Back to Dashboard

NDA 021610 describes OPANA ER, which is a drug marketed by Endo Pharms and is included in two NDAs. It is available from four suppliers. There are ten patents protecting this drug and six Paragraph IV challenges. Additional details are available on the OPANA ER profile page.

The generic ingredient in OPANA ER is oxymorphone hydrochloride. There are nine drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the oxymorphone hydrochloride profile page.
Summary for 021610
Tradename:OPANA ER
Applicant:Endo Pharms
Ingredient:oxymorphone hydrochloride
Patents:1
Therapeutic Class:Analgesics
Formulation / Manufacturing:see details
Pharmacology for NDA: 021610
Mechanism of ActionFull Opioid Agonists
Medical Subject Heading (MeSH) Categories for 021610
Suppliers and Packaging for NDA: 021610
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
OPANA ER oxymorphone hydrochloride TABLET, EXTENDED RELEASE;ORAL 021610 NDA Rebel Distributors Corp 21695-948 E 21695-948-60
OPANA ER oxymorphone hydrochloride TABLET, EXTENDED RELEASE;ORAL 021610 NDA Rebel Distributors Corp 21695-949 E 21695-949-60

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:TABLET, EXTENDED RELEASE;ORALStrength5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**
Approval Date:Jun 22, 2006TE:RLD:No
Patent:➤ Try a Free TrialPatent Expiration:Feb 4, 2023Product Flag?YSubstance Flag?Delist Request?
Patented Use:RELIEF OF MODERATE TO SEVERE PAIN

Profile for product number 002

Active Rx/OTC/Discontinued:DISCNDosage:TABLET, EXTENDED RELEASE;ORALStrength10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**
Approval Date:Jun 22, 2006TE:RLD:No
Patent:➤ Try a Free TrialPatent Expiration:Feb 4, 2023Product Flag?YSubstance Flag?Delist Request?
Patented Use:RELIEF OF MODERATE TO SEVERE PAIN

Profile for product number 003

Active Rx/OTC/Discontinued:DISCNDosage:TABLET, EXTENDED RELEASE;ORALStrength20MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**
Approval Date:Jun 22, 2006TE:RLD:No
Patent:➤ Try a Free TrialPatent Expiration:Feb 4, 2023Product Flag?YSubstance Flag?Delist Request?
Patented Use:RELIEF OF MODERATE TO SEVERE PAIN

Expired US Patents for NDA 021610

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Endo Pharms OPANA ER oxymorphone hydrochloride TABLET, EXTENDED RELEASE;ORAL 021610-002 Jun 22, 2006 ➤ Try a Free Trial ➤ Try a Free Trial
Endo Pharms OPANA ER oxymorphone hydrochloride TABLET, EXTENDED RELEASE;ORAL 021610-001 Jun 22, 2006 ➤ Try a Free Trial ➤ Try a Free Trial
Endo Pharms OPANA ER oxymorphone hydrochloride TABLET, EXTENDED RELEASE;ORAL 021610-001 Jun 22, 2006 ➤ Try a Free Trial ➤ Try a Free Trial
Endo Pharms OPANA ER oxymorphone hydrochloride TABLET, EXTENDED RELEASE;ORAL 021610-007 Feb 29, 2008 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Farmers Insurance
Moodys
Daiichi Sankyo
Harvard Business School
Baxter
Chubb
McKinsey
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.